Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes.~* Participants must meet the following IOP requirements at Visit 3~* mean/median IOP ≥ 24 mmHg at a minimum of 2 time points in the same eye~* IOP ≤ 36 mmHg at all 3 measurement time points in both eyes.~* Participants with a best-corrected visual acuity (BCVA), using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent of approximately 20/100) or better in either eye.~Exclusion Criteria:~* Participants with known hypersensitivity or contraindications to latanoprost, NO treatment, timolol maleate, other beta-adrenergic receptor antagonists or any of the ingredients in the study drugs.~* Participants with a central corneal thickness greater than 600 μm in either eye.~* Participants with advanced glaucoma and participants with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.~* Participants who do not have an intact posterior capsule in either eye .~* Participants with aphakia in either eye.~* Participants with previous or active corneal disease in either eye.~* Participants with current or a history of severe dry eye in either eye.~* Participants with current or a history of optic disc hemorrhage in either eye.~* Participants with current or a history of central/branch retinal vein or artery occlusion in either eye.~* Participants with current or a history of macular edema in either eye.~* Participants with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and participants with angle closure,congenital, and secondary glaucoma, and participants with history of angle closure in either eye.~* Participants with a diagnosis of a clinically significant or progressive retinal disease in either eye.~* Participants with any intraocular infection or inflammation in either eye within 3 months(90 days) prior to Visit 1 (Screening).~* Participants with a history of ocular laser surgery in either eye within the 3 months(90 days) prior to Visit 1 (Screening).~* Participants with a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOL-303259-X (Type: EXPERIMENTAL): BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
- Timolol (Type: ACTIVE_COMPARATOR): Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).